Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272563 | PMC |
http://dx.doi.org/10.1158/1940-6207.CAPR-22-0208 | DOI Listing |
Br J Cancer
May 2021
Cancer Biology Group, Department of Anatomy, The University of Hong Kong, 1/F, Faculty of Medicine Building, 21 Sassoon Road, Hong Kong, Hong Kong.
Cancer Prev Res (Phila)
April 2015
Department of Medicine, Weill Cornell Medical College, New York, New York.
Different mechanisms contribute to the development of sporadic, hereditary and colitis-associated colorectal cancer. Inhibitor of DNA binding/differentiation (Id) proteins act as dominant-negative antagonists of basic helix-loop-helix transcription factors. Id1 is a promising target for cancer therapy, but little is known about its role in the development of colon cancer.
View Article and Find Full Text PDFCancer Res
November 2010
Case Comprehensive Cancer Center Research Laboratories, The Division of General Medical Sciences-Oncology, Department of Pharmacology, Case Western Reserve University, and Department of Urology, University Hospitals of Cleveland, Cleveland, Ohio 44106, USA.
Insulin-like growth factor (IGF) I and bone morphogenetic proteins (BMP) are critical regulators of prostate tumor cell growth. In this report, we offer evidence that a critical support of IGF-I in prostate cancer is mediated by its ability to suppress BMP4-induced apoptosis and Smad-mediated gene expression. Suppression of BMP4 signaling by IGF-I was reversed by chemical inhibitors of phosphoinositide 3-kinase (PI3K), Akt, or mTOR; by enforced expression of wild-type PTEN or dominant-negative PI3K; or by small hairpin RNA-mediated silencing of mTORC1/2 subunits Raptor or Rictor.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!